Genetics - STAT

In the Lab By Associated Press

Lab tests show risks of using CRISPR gene editing on embryos

In the Lab By Andrew Joseph

The CRISPR story: How a basic research discovery changed science and led to a Nobel

In the Lab By Sharon Begley

Dust off the crystal ball: It’s time for STAT’s 2020 Nobel Prize predictions

Health By Kate Sheridan

Early research from 23andMe strengthens link between blood types and Covid-19

First Opinion By Wolfram Nothaft, Gregory Moore, and Yann Le Cam

Using telehealth to revolutionize the speed of making rare disease diagnoses

Health Tech By Rebecca Robbins

STAT+ Conversations: 23andMe CEO says spit kit sales are picking up during the Covid-19 pandemic

Biotech By Elizabeth Cooney

Wary hemophilia patients say they’re willing to wait longer for a safe gene therapy

In the Lab By Rebecca Robbins

Genomic sequencing to screen newborns raises more false alarms than routine blood tests, study finds

Health Tech By Erin Brodwin

Blackstone agrees to buy Ancestry in $4.7 billion deal

Pharma By Matthew Herper

Cancer drug is the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration

In the Lab By Sharon Begley

Gene-editing discovery could point the way toward a ‘holy grail’: cures for mitochondrial diseases

Biotech By Matthew Herper

Two patients die in Audentes gene therapy study, heightening concerns over high-dose treatments

In the Lab By Sharon Begley

In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys

The Readout LOUD By Rebecca Robbins, Damian Garde, and Adam Feuerstein

He speaks at Black churches about genetics — and has some ideas about how to fix his field’s diversity problem

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: The latest on treating Covid-19, vaccine politics, and diversifying genetics

Health By Rebecca Robbins

23andMe says it’s ‘part of the problem’ on racial inequity. We asked geneticists what the company can do about it

First Opinion By Matthias Evers and Michael Chui

The Bio Revolution is changing business and society

Health By Rebecca Robbins

Hospital records hold valuable Covid-19 data. Making it usable is time-consuming work

Health By Rebecca Robbins

23andMe study to recruit sickest Covid-19 patients in bid to unravel role of genetics in disease

Biotech By Sharon Begley

Deluge of genome editing therapies ends research drought for sickle cell disease

Biotech By Elizabeth Cooney

Prominent Broad Institute scientist leaves to lead R&D at Genentech

Health By Rebecca Robbins, Damian Garde, and Adam Feuerstein

‘Science is very much a part of culture’: Siddhartha Mukherjee dives into the history of genetics in a new Ken Burns film

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Pandemic exit strategies, how the outbreak affects patients, and Ken Burns takes on DNA

Politics By Rebecca Robbins

Genetic counselors push for permission to hold virtual visits with seniors covered by Medicare

Biotech By Andrew Joseph

Most Read

23andMe had devastating news about my health. I wish a person had delivered it

Human reproductive cloning: The curious incident of the dog in the night-time

23andMe’s next challenge: ensuring its customers can get drugs developed with their data

Real-time gene sequencing can help control — and may someday prevent — pandemics

The U.S. must do some heavy lifting to prepare for heritable genome editing

Our child received a devastating diagnosis before she was born. We decided to protect her

Expert panel lays out guidelines for germline editing, while warning against pursuit of ‘CRISPR babies’

5 important ways Henrietta Lacks changed medical science

All Coverage

Lab tests show risks of using CRISPR gene editing on embryos

The CRISPR story: How a basic research discovery changed science and led to a Nobel

Dust off the crystal ball: It’s time for STAT’s 2020 Nobel Prize predictions

Early research from 23andMe strengthens link between blood types and Covid-19

Using telehealth to revolutionize the speed of making rare disease diagnoses

STAT+ Conversations: 23andMe CEO says spit kit sales are picking up during the Covid-19 pandemic

Wary hemophilia patients say they’re willing to wait longer for a safe gene therapy

Genomic sequencing to screen newborns raises more false alarms than routine blood tests, study finds

Blackstone agrees to buy Ancestry in $4.7 billion deal

Cancer drug is the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration

Gene-editing discovery could point the way toward a ‘holy grail’: cures for mitochondrial diseases

Two patients die in Audentes gene therapy study, heightening concerns over high-dose treatments

In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys

He speaks at Black churches about genetics — and has some ideas about how to fix his field’s diversity problem

Listen: The latest on treating Covid-19, vaccine politics, and diversifying genetics

23andMe says it’s ‘part of the problem’ on racial inequity. We asked geneticists what the company can do about it

The Bio Revolution is changing business and society

Hospital records hold valuable Covid-19 data. Making it usable is time-consuming work

23andMe study to recruit sickest Covid-19 patients in bid to unravel role of genetics in disease

Deluge of genome editing therapies ends research drought for sickle cell disease

Prominent Broad Institute scientist leaves to lead R&D at Genentech

‘Science is very much a part of culture’: Siddhartha Mukherjee dives into the history of genetics in a new Ken Burns film

Listen: Pandemic exit strategies, how the outbreak affects patients, and Ken Burns takes on DNA

Genetic counselors push for permission to hold virtual visits with seniors covered by Medicare

Gene and cell therapies continue growth in patients, financing, and costs